You are here: Geisinger Medical
Laboratories > Test
Catalog
Geisinger Medical Laboratories Test Catalog
ALPHA-FETOPROTEIN TUMOR MARKER |
||
Geisinger Epic Procedure Code: LAB1712
Geisinger Epic ID: 6445
|
||
SPECIMEN COLLECTION |
||
Specimen type: |
Serum | |
Preferred collection container: |
||
Alternate Collection Container: |
Gold-top (serum separator) microcollection tube
|
|
Specimen required: |
1 mL of serum; minimum 0.5 mL. | |
Special notes: |
For maternal serum testing please order MSAFP. | |
| SPECIMEN PROCESSING |
||
Specimen processing instructions: |
Allow serum to clot. Centrifuge to separate serum within 2 hours of collection. | |
Transport temperature: |
Refrigerated (preferred) or frozen. | |
Specimen stability: |
Stable 14 days at 2-8°C, 3 months frozen.. | |
Rejection criteria: |
Lipemic, icteric, or hemolyzed specimens or if stability limit has been exceeded. | |
TEST DETAILS |
||
Reference interval: |
0-8.3 ng/mL. | |
Additional information: |
For maternal serum prenatal screen, please order maternal serum AFP. | |
CPT code(s): |
82105 | |
| Note: The billing party has sole responsibility for CPT coding. Any questions regarding coding should be directed to the payer being billed. The CPT codes provided by GML are based on AMA guidelines and are for informational purposes only. | ||
Test includes: |
Alpha-fetoprotein value in ng/mL. | |
Methodology: |
Roche Electrochemiluminescence Immunoassay. Patient results determined by assays using different manufacturers or methods may not be comparable. |
|
Synonyms: |
AFP Tumor marker
|
|
Clinical significance: |
Elevated AFP levels have been observed in patients with nonseminomatous testicular cancer. Serum AFP is frequently elevated in benign hepatic conditions such as acute viral hepatitis, chronic active hepatitis and cirrhosis. Conditions of pregnancy, ataxia, telangiectasia and hereditary tyrosinemia have also presented with elevated concentrations of AFP. | |
Doctoral Director(s:) |
Hoi-Ying Elsie Yu PhD, DABCC, FADLM | |
| Review Date: | 02/13/2024 | |